Justification for the selection of a candidate CoRAP substance

Substance Name (Public Name): p-Cresol

Chemical Group: Organic

EC Number: 203-398-6

CAS Number: 106-44-5

Submitted by: UK CA

Published: 20/03/2013

NOTE

This document has been prepared by the evaluating Member State given in the CoRAP update.

Contents

| 1 | | NTITY OF THE SUBSTANCE Name and other identifiers of the substance | 3 |
|---|---------------------------------|---|----------------------------|
| 2 | 2.1 | ASSIFICATION AND LABELLING Harmonised Classification in Annex VI of the CLP Proposal for Harmonised Classification in Annex VI of the CLP Self classification | 4 4 4 |
| 3 | 3.1 3.2 3.3 3.4 3.5 | TIFICATION FOR THE SELECTION Legal basis for the proposal Grounds for concern Information on aggregated tonnage and uses Other completed/ongoing regulatory processes Information to be requested to clarify the suspected risk Potential follow-up and link to risk management | 4 5 5 6 6 6 |

1 IDENTITY OF THE SUBSTANCE

1.1 Name and other identifiers of the substance

Table 1: Substance identity

| Public Name: | p-Cresol | | | | |
|--|---|--|--|--|--|
| EC number: | 203-398-6 | | | | |
| EC name: | p-Cresol | | | | |
| CAS number (in the EC inventory): | 106-44-5 | | | | |
| CAS number: | 106-44-5 | | | | |
| CAS name: | Phenol, 4-methyl- | | | | |
| IUPAC name: | 4-methylphenol | | | | |
| Index number in Annex VI of the CLP Regulation | 604-004-00-8 | | | | |
| Molecular formula: | C ₇ H ₈ O | | | | |
| Molecular weight or molecular weight range: | 108 | | | | |
| Synonyms: | 1-Hydroxy-4-methylbenzene, 4-Cresol, 4-Hydroxytoluene, p-Hydroxytoluene, p- Methylhydroxybenzene, p-Methylphenol, p- Oxytoluene, p-Cresol (8CI), p-cresol, p-Cresylic acid, p-Tolyl alcohol | | | | |

Type of substance ⊠ Mono-constituent □ Multi-constituent □ UVCB

Structural formula:

2 CLASSIFICATION AND LABELLING

2.1 Harmonised Classification in Annex VI of the CLP

Index number: 604-004-00-8

Acute Tox. 3*; H311; Toxic in contact with skin.

Acute Tox. 3*; H301; Toxic if swallowed.

Skin Corr. 1B; H314; Causes severe skin burns and eye damage.

(*Classification also applicable for m-cresol, o-cresol & mix-cresol).

2.2 Proposal for Harmonised Classification in Annex VI of the CLP

Not applicable.

2.3 Self classification

Self-classification given on the dissemination site is consistent with harmonised classification and additionally includes;

Aquatic Chronic 3; H412; Harmful to aquatic life with long lasting effects.

Additional classifications in the inventory;

Skin Corr. 1C; H314; causes severe skin burns and eye damage.

Eye Dam. 1; H318; Causes severe eye damage.

STOT SE 1; H370; causes damage to organs.

3 JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE

| 3.1 Legal basis for the proposal | | | | | | | | | |
|---|---------|------------------|-----------------------|------------------|-----------------------|--|--|--|--|
| □ Article 44(1) (refined prioritisation criteria for substance evaluation) | | | | | | | | | |
| ☐ Article 45(5) (Member State priority) | | | | | | | | | |
| | | | | | | | | | |
| 3.2 Grounds for concern | | | | | | | | | |
| | | ⊠ Wide disper | sive use | | ☐ Cumulative exposure | | | | |
| ☐ (Suspected) Sensitiser | | ⊠ Consumer use | | | ☐ High RCR | | | | |
| ☐ (Suspected) PBT | | ☐ Exposure of | sensitive populatio | ns | ☐ Aggregated tonnage | | | | |
| Suspected endocrine dis | sruptor | ☐ Other (prov | ide further details b | elow) | | | | | |
| The results of several screening tools for endocrine disruption suggest p-cresol may be an endocrine disruptor. Due to its use in consumer products further investigation is needed. | | | | | | | | | |
| In addition, an increased incidence of tumours was reported in carcinogenicity studies conducted with a mixture of 60:40 m/p cresol. Therefore, a review of the carcinogenic potential of p-Cresol is also required. | | | | | | | | | |
| 3.3 Information on aggregated tonnage and uses | | | | | | | | | |
| ☐ 1 - 10 tpa | | ☐ 10 - 100 tpa | | ☐ 100 - 1000 tpa | | | | | |
| ☐ 1000 - 10,000 tpa | | ☑ 10,000 - 10 | 0,000 tpa | | | | | | |
| ☐ 100,000 - 1000,000 tpa | a | ☐ > 1000,000 tpa | | | | | | | |
| ☐ Confidential | | | | | | | | | |
| Tonnage band given on the dissemination site is 10,000 – 100,000 tpa. | | | | | | | | | |
| ☐ Industrial use | ☐ Profe | essional use | ☐ Consumer us | е | ☐ Closed System | | | | |
| Industrial use: use in polymer production use in the processing of solid and liquid polymers use as an isolated intermediate for chemical synthesis use as a solvent for electric wire enameling Article service life Solvent in the pharmaceutical industry | | | | | | | | | |

article service life

Consumer use:

3.4 Other completed/ongoing regulatory processes that may affect suitability for substance evaluation

| ☐ Compliance check fi | nal decision | ☐ Dangerous substances Directive 67/548/EEC | | | | | | | |
|---|-------------------------|---|--|-----------------------------------|--|--|--|--|--|
| ☐ Testing proposal | | ☐ Existing Substances Regulation 793/93/EEC | | | | | | | |
| ☐ Annex VI (CLP) | | ☐ Plant Protection Products Regulation 91/414/EEC | | | | | | | |
| ☐ Annex XV (SVHC) | | | ☐ Biocidal Products Directive 98/8/EEC | | | | | | |
| ☐ Annex XIV (Authoris | sation) | | ☑ Other (provide further details below) | | | | | | |
| Annex XVII (Restriction) | | | | | | | | | |
| p-cresol been reviewed (as part of a category) under the OECD SIDS program (http://webnet.oecd.org/hpv/ui/SIDS Details.aspx?id=5b4d4ad9-0990-41c0-aa92-10f8ecb7acb6) | | | | | | | | | |
| 3.5 Information to be requested to clarify the suspected risk | | | | | | | | | |
| ☐ Information on toxion | cological properties | | ☐ Information on physico-chemical properties | | | | | | |
| ☐ Information on fate | and behaviour | ☑ Information on exposure | | | | | | | |
| ☐ Information on ecot | oxicological properties | | ☐ Information on uses | | | | | | |
| ☐ Other (provide furth | ner details below) | | | | | | | | |
| The following may be | e needed; | | | | | | | | |
| Further information t | to clarify the endocrin | e disrı | uption potential | and/or carcinogenicity. | | | | | |
| Clarification on the exposure assessments | | | | | | | | | |
| 3.6 Potential follow-up and link to risk management | | | | | | | | | |
| Restriction | ☐ Harmonised C&L | ☐ Au | uthorisation | ☐ Other (provide further details) | | | | | |
| This will depend on the outcome of the evaluation. | | | | | | | | | |